...
首页> 外文期刊>Journal of neuro-oncology. >Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.
【24h】

Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.

机译:影响颅内变性间变性少突神经胶质瘤患者预后的因素:单次机构审查70例患者。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor. In this study, we assessed the factors affecting the prognosis of AO patients. Seventy AO patients were recruited from 2001 to 2006 in Shanghai Huashan Hospital of Fudan University; all were treated surgically. Kaplan-Meier survival analysis and Cox regression analysis were used to analyze the prognostic effects of 14 different factors, which were selected from clinical, radiological, pathological, and treatment variables. The results showed that chemotherapy, age, primary or secondary tumors, preoperative Karnofsky Performance Scale (KPS) scores, the presence of epilepsy at initial presentation, radiological contrast infusion, and neurological parameters all correlated with the prognosis of the patients. Furthermore, Cox multivariate analysis also showed that the age (P < 0.048), primary or secondary tumors (P < 0.010), and chemotherapy (P < 0.010) were significantly correlated with the prognosis of the patients. Age and chemotherapy correlated with the prognosis of AO. The patients younger than 50 years old and who received regular chemotherapy were likely to achieve a good outcome. Moreover, individualized treatment after molecular biological typing of AO may improve the prognosis of AO.
机译:间变性少突胶质细胞瘤(AO)是一种罕见的颅内肿瘤,预后较差。在这项研究中,我们评估了影响AO患者预后的因素。从2001年至2006年,在复旦大学附属上海华山医院招募了70例AO患者。全部接受了手术治疗。使用Kaplan-Meier生存分析和Cox回归分析来分析14种不同因素的预后效果,这些因素选自临床,放射学,病理学和治疗变量。结果表明,化疗,年龄,原发或继发性肿瘤,术前卡诺夫斯基绩效量表(KPS)评分,初次出现癫痫病,放射对比输注和神经系统参数均与患者的预后相关。此外,Cox多变量分析还显示,年龄(P <0.048),原发性或继发性肿瘤(P <0.010)和化疗(P <0.010)与患者的预后显着相关。年龄和化疗与AO的预后相关。年龄小于50岁且接受常规化疗的患者可能会取得良好的疗效。此外,对AO进行分子生物学分型后的个体化治疗可改善AO的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号